Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14228267 | 0.94 | ALDH1A1 (0.57) | ALDH1A1HPGDAR | |
| SCHEMBL12180531 | 0.89 | ALDH1A1 (0.51) | ALDH1A1HPGDGAAMAPTAR | |
| SCHEMBL14228412 | 0.84 | ALDH1A1 (0.50) | ALDH1A1HPGDGAAMAPTTHRB | |
| SCHEMBL28035088 | 0.83 | ALDH1A1 (0.63) | ALDH1A1HPGDAR | |
| SCHEMBL7608578 | 0.83 | ALDH1A1 (0.63) | ALDH1A1HPGDAR | |
| SCHEMBL3715087 | 0.83 | ALDH1A1 (0.63) | ALDH1A1HPGDAR | |
| SCHEMBL28425205 | 0.83 | ALDH1A1 (0.63) | ALDH1A1HPGDAR | |
| SCHEMBL8448469 | 0.83 | ALDH1A1 (0.63) | ALDH1A1HPGDAR | |
| SCHEMBL2465179 | 0.83 | ALDH1A1 (0.64) | ALDH1A1HPGDNPSR1AR | |
| SCHEMBL28051296 | 0.83 | ALDH1A1 (0.64) | ALDH1A1HPGDGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846366-B1 | NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-7718703-B2 | Norvaline derivative and method for preparation thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | SLC38A7, SLC7A1, SLC6A7 | ALDH1A1 2442/4885HPGD 1808/4885GAA 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.